Saturday January 10, 2009
On fospropofol disodium (LUSEDRA)

FDA has recently approved Fospropofol for monitored anesthesia care sedation in adult patients undergoing diagnostic or therapeutic procedures 1.

Fospropofol is a water-soluble prodrug of the propofol. Fospropofol is metabolized into propofol by the liver. Because of this extra metabolism, blood levels of propofol after the administration of a bolus of fospropofol reach lower peak levels than for an equipotent dose of propofol and also lesser sedative effect. This lower sedative effect make it more desirable to use for procedures such as upper GI endoscopy, colonoscopy, bronchoscopy, cardioversion as well as other bedside surgical procedures.

Another advantage of fospropofol is that, being water-soluble, the problems associated with lipid formulated propofol e.g., pain at the IV catheter site, potential for hyperlipidemia with long-term administration, and an increased chance for bacteremia are expected to be less frequent.

It takes about 4-5 minutes to achieve desire sedative level so its important to have patience before administrating second dose. The recommended maximum dose is 12.5 mg/kg. In this month of chest 2, optimum dose of 6.5 mg/kg is described for patients undergoing flexible bronchoscopy.



Reference: click

1. Lusedra - fda.gov

2. A Phase 3, Randomized, Double-Blind Study To Assess the Efficacy and Safety of Fospropofol Disodium Injection for Moderate Sedation in Patients Undergoing Flexible Bronchoscopy - CHEST January 2009 vol. 135 no. 1 41-47